A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

AB0762 Fficacy and Safety of Nemartro(Nem®-Stratum Nutrition) Brand Eggshell Membrane in Patients with Knee Osteoarthritis Accompanying with Joint Pain and Stiffness. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Crossover Study

(2016) N. Eskiyurt et al.   ANNALS OF THE RHEUMATIC DISEASES

Thyroid Patient Salivary Radioiodine Transit and Dysfunction Assessment Using Chewing Gums

(2016) Demetrios Okkalides   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma

(2016) Tadaaki Arizumi et al.   DIGESTIVE DISEASES

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

(2016) Kenji Ikeda et al.   JOURNAL OF GASTROENTEROLOGY

Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan

(2016) Masatoshi Kudo et al.   Liver Cancer

Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma

(2016)   Liver Cancer

Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria)

(2015) Masatoshi Kudo et al.   DIGESTIVE DISEASES

Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

(2015) Calin Cainap et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

(2015) Andrew X Zhu et al.   LANCET ONCOLOGY

Locoregional Therapy for Hepatocellular Carcinoma

(2015)   Liver Cancer

Surgical and Locoregional Therapy of HCC: TACE

(2015) Masakatsu Tsurusaki et al.   Liver Cancer

Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma

(2015) Tadaaki Arizumi et al.   Liver Cancer

Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan

(2015) Masatoshi Kudo   Liver Cancer

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

(2014) Masatoshi Kudo et al.   HEPATOLOGY

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

(2014) Andrew X. Zhu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update

(2014) Masatoshi Kudo et al.   ONCOLOGY

Validation of the Criteria of Transcatheter Arterial Chemoembolization Failure or Refractoriness in Patients with Advanced Hepatocellular Carcinoma Proposed by the LCSGJ

(2014) Tadaaki Arizumi et al.   ONCOLOGY

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

(2013) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

(2013) Josep M. Llovet et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

(2013) Ann-Lii Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

(2011) Masatoshi Kudo et al.   EUROPEAN JOURNAL OF CANCER

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE